All Posts
Scientific Update: FGFR2 Pathway Activation as a Therapeutic Biomarker for FGFR2 Inhibitors
Fibroblast growth factor receptor 2 (FGFR2) is among cholangiocarcinoma's most frequently altered genes. Chromosomal fusions and gene rearrangements are particularly…
From Football to Fine Art - A family finds creative ways to raise funds and awareness
In the summer of 2022, Taylor's family received devastating news: her dad had been diagnosed with cholangiocarcinoma. As a first…
Strength in Community, Hope in Research: Creating a World Free of Cholangiocarcinoma
In October of 2005, my brother, Mark, was diagnosed with cholangiocarcinoma, a rare and aggressive cancer of the bile duct,…
Scientific Update: Phase II Study of a Novel Immunotherapy Combination for Cholangiocarcinoma
Kelly Butler The first line of treatment for unresectable cholangiocarcinoma is gemcitabine plus cisplatin, a combination of two traditional chemotherapies…
NCI/CTEP 10276: A Phase 1/2 Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Study Name NCI/CTEP 10276: A Phase 1/2 Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with…
CholangioConnect in 2023
1,158 Connections Created a New Grief Toolkit Designed a Drip Onboarding Email Series Initiated Interpretation Services Established a New CholangioConnect…
Alie Plouff has been honored with the Daily Point of Light Award
CCF is delighted to announce that Alie Plouff has been honored with the Daily Point of Light Award on January…
New Year’s Resolution
Welcome to 2024, a year that marks the beginning of a new chapter for all of us at the Cholangiocarcinoma…
Team CCF makes major strides
2023 was an incredible year for Team CCF. Team members participated in five marathons across the country. In 2023, Team…
Jingle for Janet 2023
The Jingle for Janet Fundraiser, an annual event dedicated to honoring the memory of Janet Parker and raising funds for…